Isoform-selective agonists and antagonists of the
lysophosphatidic acid (LPA)
G-protein-coupled receptors (GPCRs) have important potential applications in cell biology and
therapy. LPA GPCRs regulate
cancer cell proliferation, invasion, angiogenesis, and biochemical resistance to
chemotherapy- and
radiotherapy-induced apoptosis. LPA and its analogues are also feedback inhibitors of the
enzyme lysophospholipase D (lysoPLD, also known as autotaxin), a central regulator of invasion and
metastasis. For
cancer therapy, the ideal therapeutic profile would be a metabolically stabilized pan-
LPA receptor antagonist that also inhibits lysoPLD. Herein we describe the synthesis of a series of novel alpha-substituted methylene
phosphonate analogues of LPA. Each of these analogues contains a hydrolysis-resistant
phosphonate mimic of the labile monophosphate of natural LPA. The pharmacological properties of these phosphono-LPA analogues were characterized in terms of
LPA receptor subtype-specific agonist and antagonist activity using Ca(2+) mobilization assays in RH7777 and CHO cells expressing the individual LPA GPCRs. In particular, the methylene
phosphonate LPA analogue is a selective LPA(2) agonist, whereas the corresponding alpha-hydroxymethylene
phosphonate is a selective LPA(3) agonist. Most importantly, the alpha-bromomethylene and alpha-chloromethylene
phosphonates show pan-
LPA receptor subtype antagonist activity. The alpha-bromomethylene
phosphonates are the first reported antagonists for the LPA(4) GPCR. Each of the alpha-substituted methylene
phosphonates inhibits lysoPLD, with the unsubstituted methylene
phosphonate showing the most potent inhibition. Finally, unlike many LPA analogues, none of these compounds activate the intracellular
LPA receptor PPARgamma.